Randomised trial assessing the efficacy of the partial interruption of the inferior vena cava by an optional vena caval filter in the prevention of the recurrence of pulmonary embolism. PREPIC 2 trial: Prevention of embolic recurrences by caval interruption (prospective, multicentric, randomised, open trial);Essai randomisé évaluant l'efficacité d'une interruption partielle de la veine cave inférieure par un filtre cave optionnel sur la prévention des récidives d'embolies pulmonaires. Étude PREPIC 2 : prévention des récidives emboliques par interruption cave (étude prospective, multicentrique, randomisée, en ouvert)

Revue de Pneumologie Clinique

Volumn 64, Issue 6, 2008, Pages 328-331

  Mismetti, P ^a,b,c  

^a INSERM   (France)

^b University Jean Monnet of Saint Etienne EA3065   (France)

^c SERVICE DE NEUROLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; INFERIOR CAVA VEIN; LUNG EMBOLISM; OPEN STUDY; PATIENT SELECTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; SURGICAL TECHNIQUE; THROMBOSIS PREVENTION; VENA CAVA FILTER; ARTICLE;

HUMANS; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; VENA CAVA FILTERS;

EID: 59649085817     PISSN: 07618417     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneumo.2008.09.011     Document Type: Review

References (10)

1. Decousus H., Leizorovicz A., Parent F., Page Y., Tardy B., Girard P., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. [Prévention du risque d'embolie pulmonaire par interruption]. Cave Study Group. N Engl J Med 338 (1998) 409-415
2. The PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC randomized study. Circulation 2005;112:416-22.
3. Büller H.R., Agnelli G., Hull R.D., Hyers T.M., Prins M.H., and Raskob G.E. Antithrombotic therapy for venous thromboembolic disease. Chest 126 (2004) 401S-428S
4. Laporte S., Mismetti P., Decousus H., Uresandi F., Otero R., Lobo J.L., et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism. Findings from the RIETE registry. Circulation 117 (2008) 1711-1716
5. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., Lohse C.M., O'Fallon W.M., et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 86 (2001) 452-463
6. Mismetti P, Quenet S, Levine M, Merli G, Decousus H, Derobert E, et al. Enoxaparin in the treatment of deep-vein thrombosis with or without pulmonary embolism: an individual-patient-data meta-analysis. Chest 2005;128:2203-10.
7. Douketis J.D., Kearon C., Bates S., Duku E.K., and Ginsberg J.S. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 279 (1998) 458-462
8. Buller H.R., Davidson B.L., Decousus H., Gallus A., Gent M., Piovella F., et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349 (2003) 1695-1702
9. Buller H.R., Davidson B.L., Decousus H., Gallus A., Gent M., Piovella F., et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep-vein thrombosis: a randomized, double-blind non-inferiority trial. Ann Intern Med 140 (2004) 867-873
10. Mismetti P., Palluy-Bachongy A., Epinat M., Moulin N., Barral F., and Décousus H. Interruptions de la veine cave inférieure. In: Diehl J.L., Meyer G., and Perrier A. (Eds). Embolie pulmonaire (2005), Elsevier, Paris